Table 1 Open in new tab Patient...

	Total	First diagnosed	Paroxysmal	Persistent	Long-standing persistent	Permanent	P-value
N	4107	292	1720	982	414	699
Age (years)^a	68.5 ± 11.8	68.3 ± 12.2	67.3 ± 12.2	66.3 ± 11.0	71.1 ± 11.2	73.2 ± 11.0	<0.001^b
Age (years)^c	69.0 (61.0–77.0)	68.0 (60.0–77.0)	68.0 (60.0–76.0)	67.0 (59.0–74.0)	72.0 (64.0–79.0)	74.0 (66.0–81.0)
Age (years, %)
≤65	37.8 (1553/4107)	39.0 (114/292)	41.9 (721/1720)	44.5 (437/982)	29.5 (122/414)	22.8 (159/699)	<0.001^d
>65	62.2 (2554/4107)	61.0 (178/292)	58.1 (999/1720)	55.5 (545/982)	70.5 (292/414)	77.3 (540/699)
Gender (%)
Male	65.5 (2689/4107)	61.6 (180/292)	63.6 (1094/1720)	71.1 (698/982)	66.7 (276/414)	63.1 (441/699)	<0.001^d
Female	34.5 (1418/4107)	38.4 (112/292)	36.4 (626/1720)	28.9 (284/982)	33.3 (138/414)	36.9 (258/699)
CHA₂DS₂-VASc (%)
Low risk	12.9 (529/4107)	13.7 (40/292)	17.7 (304/1720)	12.1 (119/982)	10.4 (43/414)	3.3 (23/699)	<0.001^d
Moderate risk	13.9 (572/4107)	9.6 (28/292)	15.3 (263/1720)	18.5 (182/982)	12.6 (52/414)	6.7 (47/699)
High risk	73.2 (3006/4107)	76.7 (224/292)	67.0 (1153/1720)	69.4 (681/982)	77.1 (391/414)	90.0 (629/699)
HAS-BLED Score class (%)
0–2	86.2 (3540/4107)	85.6 (250/292)	90.4 (1554/1720)	87.7 (861/982)	80.7 (334/414)	77.4 (541/699)	<0.001^d
≥3 or more	13.8 (567/4107)	14.4 (42/292)	9.7 (166/1720)	12.3 (121/982)	19.3 (80/414)	22.6 (158/699)
Body weight (kg)^a	67.2 ± 13.7	68.1 ± 15.4	66.3 ± 13.0	68.5 ± 13.9	67.1 ± 13.6	67.1 ± 14.1	0.002^b
Creatinine (μmol/L)^a	95.7 ± 55.7	98.5 ± 54.6	93.6 ± 61.7	91.5 ± 42.8	100.1 ± 52.8	102.8 ± 57.1	<0.001^b
Follow-up duration (days)^a	364.1 ± 48.3	361.7 ± 46.8	364.4 ± 54.4	366.9 ± 48.2	368.4 ± 44.9	357.7 ± 30.6	<0.001^b
Follow-up duration (days)^c	365.0 (344.0–374.0)	364.0 (339.0–372.0)	365.0 (343.0–376.0)	365.0 (349.0–378.0)	365.0 (349.0–378.0)	357.0 (342.0–366.0)
Current symptoms at follow-up (%)	15.6 (618/3972)	10.2 (28/274)	19.6 (330/1683)	13.7 (131/958)	15.7 (62/395)	10.1 (67/662)	<0.001^d
Palpitations (%)	56.2 (347/618)	60.7 (17/28)	68.2 (225/330)	45.8 (60/131)	32.3 (20/62)	37.3 (25/67)	<0.001^d
Dizziness (%)	13.9 (86/618)	14.3 (4/28)	11.2 (37/330)	16.0 (21/131)	27.4 (17/62)	10.5 (7/67)	0.013^d
General non-wellbeing (%)	6.8 (42/618)	0 (0/28)	8.2 (27/330)	3.8 (5/131)	8.1 (5/62)	7.5 (5/67)	0.279^d
Fatigue (%)	10.7 (66/618)	10.7 (3/28)	9.1 (30/330)	10.7 (14/131)	12.9 (8/62)	16.4 (11/67)	0.477^d
Shortness of breath (%)	30.1 (186/618)	17.9 (5/28)	24.9 (82/330)	32.8 (43/131)	46.8 (29/62)	40.3 (27/67)	0.001^d
Chest pain (%)	15.4 (95/618)	17.9 (5/28)	13.6 (45/330)	13.0 (17/131)	22.6 (14/62)	20.9 (14/67)	0.238^d
Fear/anxiety (%)	3.2 (20/618)	0 (0/28)	4.2 (14/330)	3.1 (4/131)	1.6 (1/62)	1.5 (1/67)	0.527^d
Other (%)	3.6 (22/618)	3.6 (1/28)	1.8 (6/330)	5.3 (7/131)	8.1 (5/62)	4.5 (3/67)	0.093^d

Total

First diagnosed

Paroxysmal

Persistent

Long-standing persistent

Permanent

P-value

3989

275

1690

965

396

663

4107

292

1720

982

414

699

Age (years)^a

68.5 ± 11.8

68.3 ± 12.2

67.3 ± 12.2

66.3 ± 11.0

71.1 ± 11.2

73.2 ± 11.0

<0.001^b

Age (years)^c

69.0 (61.0–77.0)

68.0 (60.0–77.0)

68.0 (60.0–76.0)

67.0 (59.0–74.0)

72.0 (64.0–79.0)

74.0 (66.0–81.0)

Age (years, %)

≤65

37.8 (1553/4107)

39.0 (114/292)

41.9 (721/1720)

44.5 (437/982)

29.5 (122/414)

22.8 (159/699)

<0.001^d

>65

62.2 (2554/4107)

61.0 (178/292)

58.1 (999/1720)

55.5 (545/982)

70.5 (292/414)

77.3 (540/699)

Gender (%)

Male

65.5 (2689/4107)

61.6 (180/292)

63.6 (1094/1720)

71.1 (698/982)

66.7 (276/414)

63.1 (441/699)

<0.001^d

Female

34.5 (1418/4107)

38.4 (112/292)

36.4 (626/1720)

28.9 (284/982)

33.3 (138/414)

36.9 (258/699)

CHA₂DS₂-VASc (%)

Low risk

12.9 (529/4107)

13.7 (40/292)

17.7 (304/1720)

12.1 (119/982)

10.4 (43/414)

3.3 (23/699)

<0.001^d

Moderate risk

13.9 (572/4107)

9.6 (28/292)

15.3 (263/1720)

18.5 (182/982)

12.6 (52/414)

6.7 (47/699)

High risk

73.2 (3006/4107)

76.7 (224/292)

67.0 (1153/1720)

69.4 (681/982)

77.1 (391/414)

90.0 (629/699)

HAS-BLED Score class (%)

0–2

86.2 (3540/4107)

85.6 (250/292)

90.4 (1554/1720)

87.7 (861/982)

80.7 (334/414)

77.4 (541/699)

<0.001^d

≥3 or more

13.8 (567/4107)

14.4 (42/292)

9.7 (166/1720)

12.3 (121/982)

19.3 (80/414)

22.6 (158/699)

Body weight (kg)^a

67.2 ± 13.7

68.1 ± 15.4

66.3 ± 13.0

68.5 ± 13.9

67.1 ± 13.6

67.1 ± 14.1

0.002^b

Creatinine (μmol/L)^a

95.7 ± 55.7

98.5 ± 54.6

93.6 ± 61.7

91.5 ± 42.8

100.1 ± 52.8

102.8 ± 57.1

<0.001^b

Follow-up duration (days)^a

364.1 ± 48.3

361.7 ± 46.8

364.4 ± 54.4

366.9 ± 48.2

368.4 ± 44.9

357.7 ± 30.6

<0.001^b

Follow-up duration (days)^c

365.0 (344.0–374.0)

364.0 (339.0–372.0)

365.0 (343.0–376.0)

365.0 (349.0–378.0)

357.0 (342.0–366.0)

Current symptoms at follow-up (%)

15.6 (618/3972)

10.2 (28/274)

19.6 (330/1683)

13.7 (131/958)

15.7 (62/395)

10.1 (67/662)

<0.001^d

Palpitations (%)

56.2 (347/618)

60.7 (17/28)

68.2 (225/330)

45.8 (60/131)

32.3 (20/62)

37.3 (25/67)

<0.001^d

Dizziness (%)

13.9 (86/618)

14.3 (4/28)

11.2 (37/330)

16.0 (21/131)

27.4 (17/62)

10.5 (7/67)

0.013^d

General non-wellbeing (%)

6.8 (42/618)

0 (0/28)

8.2 (27/330)

3.8 (5/131)

8.1 (5/62)

7.5 (5/67)

0.279^d

Fatigue (%)

10.7 (66/618)

10.7 (3/28)

9.1 (30/330)

10.7 (14/131)

12.9 (8/62)

16.4 (11/67)

0.477^d

Shortness of breath (%)

30.1 (186/618)

17.9 (5/28)

24.9 (82/330)

32.8 (43/131)

46.8 (29/62)

40.3 (27/67)

0.001^d

Chest pain (%)

15.4 (95/618)

17.9 (5/28)

13.6 (45/330)

13.0 (17/131)

22.6 (14/62)

20.9 (14/67)

0.238^d

Fear/anxiety (%)

3.2 (20/618)

0 (0/28)

4.2 (14/330)

3.1 (4/131)

1.6 (1/62)

1.5 (1/67)

0.527^d

Other (%)

3.6 (22/618)

3.6 (1/28)

1.8 (6/330)

5.3 (7/131)

8.1 (5/62)

4.5 (3/67)

0.093^d

	Total	First diagnosed	Paroxysmal	Persistent	Long-standing persistent	Permanent	P-value
N	4107	292	1720	982	414	699
Age (years)^a	68.5 ± 11.8	68.3 ± 12.2	67.3 ± 12.2	66.3 ± 11.0	71.1 ± 11.2	73.2 ± 11.0	<0.001^b
Age (years)^c	69.0 (61.0–77.0)	68.0 (60.0–77.0)	68.0 (60.0–76.0)	67.0 (59.0–74.0)	72.0 (64.0–79.0)	74.0 (66.0–81.0)
Age (years, %)
≤65	37.8 (1553/4107)	39.0 (114/292)	41.9 (721/1720)	44.5 (437/982)	29.5 (122/414)	22.8 (159/699)	<0.001^d
>65	62.2 (2554/4107)	61.0 (178/292)	58.1 (999/1720)	55.5 (545/982)	70.5 (292/414)	77.3 (540/699)
Gender (%)
Male	65.5 (2689/4107)	61.6 (180/292)	63.6 (1094/1720)	71.1 (698/982)	66.7 (276/414)	63.1 (441/699)	<0.001^d
Female	34.5 (1418/4107)	38.4 (112/292)	36.4 (626/1720)	28.9 (284/982)	33.3 (138/414)	36.9 (258/699)
CHA₂DS₂-VASc (%)
Low risk	12.9 (529/4107)	13.7 (40/292)	17.7 (304/1720)	12.1 (119/982)	10.4 (43/414)	3.3 (23/699)	<0.001^d
Moderate risk	13.9 (572/4107)	9.6 (28/292)	15.3 (263/1720)	18.5 (182/982)	12.6 (52/414)	6.7 (47/699)
High risk	73.2 (3006/4107)	76.7 (224/292)	67.0 (1153/1720)	69.4 (681/982)	77.1 (391/414)	90.0 (629/699)
HAS-BLED Score class (%)
0–2	86.2 (3540/4107)	85.6 (250/292)	90.4 (1554/1720)	87.7 (861/982)	80.7 (334/414)	77.4 (541/699)	<0.001^d
≥3 or more	13.8 (567/4107)	14.4 (42/292)	9.7 (166/1720)	12.3 (121/982)	19.3 (80/414)	22.6 (158/699)
Body weight (kg)^a	67.2 ± 13.7	68.1 ± 15.4	66.3 ± 13.0	68.5 ± 13.9	67.1 ± 13.6	67.1 ± 14.1	0.002^b
Creatinine (μmol/L)^a	95.7 ± 55.7	98.5 ± 54.6	93.6 ± 61.7	91.5 ± 42.8	100.1 ± 52.8	102.8 ± 57.1	<0.001^b
Follow-up duration (days)^a	364.1 ± 48.3	361.7 ± 46.8	364.4 ± 54.4	366.9 ± 48.2	368.4 ± 44.9	357.7 ± 30.6	<0.001^b
Follow-up duration (days)^c	365.0 (344.0–374.0)	364.0 (339.0–372.0)	365.0 (343.0–376.0)	365.0 (349.0–378.0)	365.0 (349.0–378.0)	357.0 (342.0–366.0)
Current symptoms at follow-up (%)	15.6 (618/3972)	10.2 (28/274)	19.6 (330/1683)	13.7 (131/958)	15.7 (62/395)	10.1 (67/662)	<0.001^d
Palpitations (%)	56.2 (347/618)	60.7 (17/28)	68.2 (225/330)	45.8 (60/131)	32.3 (20/62)	37.3 (25/67)	<0.001^d
Dizziness (%)	13.9 (86/618)	14.3 (4/28)	11.2 (37/330)	16.0 (21/131)	27.4 (17/62)	10.5 (7/67)	0.013^d
General non-wellbeing (%)	6.8 (42/618)	0 (0/28)	8.2 (27/330)	3.8 (5/131)	8.1 (5/62)	7.5 (5/67)	0.279^d
Fatigue (%)	10.7 (66/618)	10.7 (3/28)	9.1 (30/330)	10.7 (14/131)	12.9 (8/62)	16.4 (11/67)	0.477^d
Shortness of breath (%)	30.1 (186/618)	17.9 (5/28)	24.9 (82/330)	32.8 (43/131)	46.8 (29/62)	40.3 (27/67)	0.001^d
Chest pain (%)	15.4 (95/618)	17.9 (5/28)	13.6 (45/330)	13.0 (17/131)	22.6 (14/62)	20.9 (14/67)	0.238^d
Fear/anxiety (%)	3.2 (20/618)	0 (0/28)	4.2 (14/330)	3.1 (4/131)	1.6 (1/62)	1.5 (1/67)	0.527^d
Other (%)	3.6 (22/618)	3.6 (1/28)	1.8 (6/330)	5.3 (7/131)	8.1 (5/62)	4.5 (3/67)	0.093^d

Total

First diagnosed

Paroxysmal

Persistent

Long-standing persistent

Permanent

P-value

3989

275

1690

965

396

663

4107

292

1720

982

414

699

Age (years)^a

68.5 ± 11.8

68.3 ± 12.2

67.3 ± 12.2

66.3 ± 11.0

71.1 ± 11.2

73.2 ± 11.0

<0.001^b

Age (years)^c

69.0 (61.0–77.0)

68.0 (60.0–77.0)

68.0 (60.0–76.0)

67.0 (59.0–74.0)

72.0 (64.0–79.0)

74.0 (66.0–81.0)

Age (years, %)

≤65

37.8 (1553/4107)

39.0 (114/292)

41.9 (721/1720)

44.5 (437/982)

29.5 (122/414)

22.8 (159/699)

<0.001^d

>65

62.2 (2554/4107)

61.0 (178/292)

58.1 (999/1720)

55.5 (545/982)

70.5 (292/414)

77.3 (540/699)

Gender (%)

Male

65.5 (2689/4107)

61.6 (180/292)

63.6 (1094/1720)

71.1 (698/982)

66.7 (276/414)

63.1 (441/699)

<0.001^d

Female

34.5 (1418/4107)

38.4 (112/292)

36.4 (626/1720)

28.9 (284/982)

33.3 (138/414)

36.9 (258/699)

CHA₂DS₂-VASc (%)

Low risk

12.9 (529/4107)

13.7 (40/292)

17.7 (304/1720)

12.1 (119/982)

10.4 (43/414)

3.3 (23/699)

<0.001^d

Moderate risk

13.9 (572/4107)

9.6 (28/292)

15.3 (263/1720)

18.5 (182/982)

12.6 (52/414)

6.7 (47/699)

High risk

73.2 (3006/4107)

76.7 (224/292)

67.0 (1153/1720)

69.4 (681/982)

77.1 (391/414)

90.0 (629/699)

HAS-BLED Score class (%)

0–2

86.2 (3540/4107)

85.6 (250/292)

90.4 (1554/1720)

87.7 (861/982)

80.7 (334/414)

77.4 (541/699)

<0.001^d

≥3 or more

13.8 (567/4107)

14.4 (42/292)

9.7 (166/1720)

12.3 (121/982)

19.3 (80/414)

22.6 (158/699)

Body weight (kg)^a

67.2 ± 13.7

68.1 ± 15.4

66.3 ± 13.0

68.5 ± 13.9

67.1 ± 13.6

67.1 ± 14.1

0.002^b

Creatinine (μmol/L)^a

95.7 ± 55.7

98.5 ± 54.6

93.6 ± 61.7

91.5 ± 42.8

100.1 ± 52.8

102.8 ± 57.1

<0.001^b

Follow-up duration (days)^a

364.1 ± 48.3

361.7 ± 46.8

364.4 ± 54.4

366.9 ± 48.2

368.4 ± 44.9

357.7 ± 30.6

<0.001^b

Follow-up duration (days)^c

365.0 (344.0–374.0)

364.0 (339.0–372.0)

365.0 (343.0–376.0)

365.0 (349.0–378.0)

357.0 (342.0–366.0)

Current symptoms at follow-up (%)

15.6 (618/3972)

10.2 (28/274)

19.6 (330/1683)

13.7 (131/958)

15.7 (62/395)

10.1 (67/662)

<0.001^d

Palpitations (%)

56.2 (347/618)

60.7 (17/28)

68.2 (225/330)

45.8 (60/131)

32.3 (20/62)

37.3 (25/67)

<0.001^d

Dizziness (%)

13.9 (86/618)

14.3 (4/28)

11.2 (37/330)

16.0 (21/131)

27.4 (17/62)

10.5 (7/67)

0.013^d

General non-wellbeing (%)

6.8 (42/618)

0 (0/28)

8.2 (27/330)

3.8 (5/131)

8.1 (5/62)

7.5 (5/67)

0.279^d

Fatigue (%)

10.7 (66/618)

10.7 (3/28)

9.1 (30/330)

10.7 (14/131)

12.9 (8/62)

16.4 (11/67)

0.477^d

Shortness of breath (%)

30.1 (186/618)

17.9 (5/28)

24.9 (82/330)

32.8 (43/131)

46.8 (29/62)

40.3 (27/67)

0.001^d

Chest pain (%)

15.4 (95/618)

17.9 (5/28)

13.6 (45/330)

13.0 (17/131)

22.6 (14/62)

20.9 (14/67)

0.238^d

Fear/anxiety (%)

3.2 (20/618)

0 (0/28)

4.2 (14/330)

3.1 (4/131)

1.6 (1/62)

1.5 (1/67)

0.527^d

Other (%)

3.6 (22/618)

3.6 (1/28)

1.8 (6/330)

5.3 (7/131)

8.1 (5/62)

4.5 (3/67)

0.093^d

Table 1

Open in new tab

Patient demography in relation to clinical subtype of atrial fibrillation

	Total	First diagnosed	Paroxysmal	Persistent	Long-standing persistent	Permanent	P-value
N	3989	275	1690	965	396	663
N	4107	292	1720	982	414	699
Age (years)^a	68.5 ± 11.8	68.3 ± 12.2	67.3 ± 12.2	66.3 ± 11.0	71.1 ± 11.2	73.2 ± 11.0	<0.001^b
Age (years)^c	69.0 (61.0–77.0)	68.0 (60.0–77.0)	68.0 (60.0–76.0)	67.0 (59.0–74.0)	72.0 (64.0–79.0)	74.0 (66.0–81.0)
Age (years, %)
≤65	37.8 (1553/4107)	39.0 (114/292)	41.9 (721/1720)	44.5 (437/982)	29.5 (122/414)	22.8 (159/699)	<0.001^d
>65	62.2 (2554/4107)	61.0 (178/292)	58.1 (999/1720)	55.5 (545/982)	70.5 (292/414)	77.3 (540/699)
Gender (%)
Male	65.5 (2689/4107)	61.6 (180/292)	63.6 (1094/1720)	71.1 (698/982)	66.7 (276/414)	63.1 (441/699)	<0.001^d
Female	34.5 (1418/4107)	38.4 (112/292)	36.4 (626/1720)	28.9 (284/982)	33.3 (138/414)	36.9 (258/699)
CHA₂DS₂-VASc (%)
Low risk	12.9 (529/4107)	13.7 (40/292)	17.7 (304/1720)	12.1 (119/982)	10.4 (43/414)	3.3 (23/699)	<0.001^d
Moderate risk	13.9 (572/4107)	9.6 (28/292)	15.3 (263/1720)	18.5 (182/982)	12.6 (52/414)	6.7 (47/699)
High risk	73.2 (3006/4107)	76.7 (224/292)	67.0 (1153/1720)	69.4 (681/982)	77.1 (391/414)	90.0 (629/699)
HAS-BLED Score class (%)
0–2	86.2 (3540/4107)	85.6 (250/292)	90.4 (1554/1720)	87.7 (861/982)	80.7 (334/414)	77.4 (541/699)	<0.001^d
≥3 or more	13.8 (567/4107)	14.4 (42/292)	9.7 (166/1720)	12.3 (121/982)	19.3 (80/414)	22.6 (158/699)
Body weight (kg)^a	67.2 ± 13.7	68.1 ± 15.4	66.3 ± 13.0	68.5 ± 13.9	67.1 ± 13.6	67.1 ± 14.1	0.002^b
Creatinine (μmol/L)^a	95.7 ± 55.7	98.5 ± 54.6	93.6 ± 61.7	91.5 ± 42.8	100.1 ± 52.8	102.8 ± 57.1	<0.001^b
Follow-up duration (days)^a	364.1 ± 48.3	361.7 ± 46.8	364.4 ± 54.4	366.9 ± 48.2	368.4 ± 44.9	357.7 ± 30.6	<0.001^b
Follow-up duration (days)^c	365.0 (344.0–374.0)	364.0 (339.0–372.0)	365.0 (343.0–376.0)	365.0 (349.0–378.0)	365.0 (349.0–378.0)	357.0 (342.0–366.0)
Current symptoms at follow-up (%)	15.6 (618/3972)	10.2 (28/274)	19.6 (330/1683)	13.7 (131/958)	15.7 (62/395)	10.1 (67/662)	<0.001^d
Palpitations (%)	56.2 (347/618)	60.7 (17/28)	68.2 (225/330)	45.8 (60/131)	32.3 (20/62)	37.3 (25/67)	<0.001^d
Dizziness (%)	13.9 (86/618)	14.3 (4/28)	11.2 (37/330)	16.0 (21/131)	27.4 (17/62)	10.5 (7/67)	0.013^d
General non-wellbeing (%)	6.8 (42/618)	0 (0/28)	8.2 (27/330)	3.8 (5/131)	8.1 (5/62)	7.5 (5/67)	0.279^d
Fatigue (%)	10.7 (66/618)	10.7 (3/28)	9.1 (30/330)	10.7 (14/131)	12.9 (8/62)	16.4 (11/67)	0.477^d
Shortness of breath (%)	30.1 (186/618)	17.9 (5/28)	24.9 (82/330)	32.8 (43/131)	46.8 (29/62)	40.3 (27/67)	0.001^d
Chest pain (%)	15.4 (95/618)	17.9 (5/28)	13.6 (45/330)	13.0 (17/131)	22.6 (14/62)	20.9 (14/67)	0.238^d
Fear/anxiety (%)	3.2 (20/618)	0 (0/28)	4.2 (14/330)	3.1 (4/131)	1.6 (1/62)	1.5 (1/67)	0.527^d
Other (%)	3.6 (22/618)	3.6 (1/28)	1.8 (6/330)	5.3 (7/131)	8.1 (5/62)	4.5 (3/67)	0.093^d

	Total	First diagnosed	Paroxysmal	Persistent	Long-standing persistent	Permanent	P-value
N	3989	275	1690	965	396	663
N	4107	292	1720	982	414	699
Age (years)^a	68.5 ± 11.8	68.3 ± 12.2	67.3 ± 12.2	66.3 ± 11.0	71.1 ± 11.2	73.2 ± 11.0	<0.001^b
Age (years)^c	69.0 (61.0–77.0)	68.0 (60.0–77.0)	68.0 (60.0–76.0)	67.0 (59.0–74.0)	72.0 (64.0–79.0)	74.0 (66.0–81.0)
Age (years, %)
≤65	37.8 (1553/4107)	39.0 (114/292)	41.9 (721/1720)	44.5 (437/982)	29.5 (122/414)	22.8 (159/699)	<0.001^d
>65	62.2 (2554/4107)	61.0 (178/292)	58.1 (999/1720)	55.5 (545/982)	70.5 (292/414)	77.3 (540/699)
Gender (%)
Male	65.5 (2689/4107)	61.6 (180/292)	63.6 (1094/1720)	71.1 (698/982)	66.7 (276/414)	63.1 (441/699)	<0.001^d
Female	34.5 (1418/4107)	38.4 (112/292)	36.4 (626/1720)	28.9 (284/982)	33.3 (138/414)	36.9 (258/699)
CHA₂DS₂-VASc (%)
Low risk	12.9 (529/4107)	13.7 (40/292)	17.7 (304/1720)	12.1 (119/982)	10.4 (43/414)	3.3 (23/699)	<0.001^d
Moderate risk	13.9 (572/4107)	9.6 (28/292)	15.3 (263/1720)	18.5 (182/982)	12.6 (52/414)	6.7 (47/699)
High risk	73.2 (3006/4107)	76.7 (224/292)	67.0 (1153/1720)	69.4 (681/982)	77.1 (391/414)	90.0 (629/699)
HAS-BLED Score class (%)
0–2	86.2 (3540/4107)	85.6 (250/292)	90.4 (1554/1720)	87.7 (861/982)	80.7 (334/414)	77.4 (541/699)	<0.001^d
≥3 or more	13.8 (567/4107)	14.4 (42/292)	9.7 (166/1720)	12.3 (121/982)	19.3 (80/414)	22.6 (158/699)
Body weight (kg)^a	67.2 ± 13.7	68.1 ± 15.4	66.3 ± 13.0	68.5 ± 13.9	67.1 ± 13.6	67.1 ± 14.1	0.002^b
Creatinine (μmol/L)^a	95.7 ± 55.7	98.5 ± 54.6	93.6 ± 61.7	91.5 ± 42.8	100.1 ± 52.8	102.8 ± 57.1	<0.001^b
Follow-up duration (days)^a	364.1 ± 48.3	361.7 ± 46.8	364.4 ± 54.4	366.9 ± 48.2	368.4 ± 44.9	357.7 ± 30.6	<0.001^b
Follow-up duration (days)^c	365.0 (344.0–374.0)	364.0 (339.0–372.0)	365.0 (343.0–376.0)	365.0 (349.0–378.0)	365.0 (349.0–378.0)	357.0 (342.0–366.0)
Current symptoms at follow-up (%)	15.6 (618/3972)	10.2 (28/274)	19.6 (330/1683)	13.7 (131/958)	15.7 (62/395)	10.1 (67/662)	<0.001^d
Palpitations (%)	56.2 (347/618)	60.7 (17/28)	68.2 (225/330)	45.8 (60/131)	32.3 (20/62)	37.3 (25/67)	<0.001^d
Dizziness (%)	13.9 (86/618)	14.3 (4/28)	11.2 (37/330)	16.0 (21/131)	27.4 (17/62)	10.5 (7/67)	0.013^d
General non-wellbeing (%)	6.8 (42/618)	0 (0/28)	8.2 (27/330)	3.8 (5/131)	8.1 (5/62)	7.5 (5/67)	0.279^d
Fatigue (%)	10.7 (66/618)	10.7 (3/28)	9.1 (30/330)	10.7 (14/131)	12.9 (8/62)	16.4 (11/67)	0.477^d
Shortness of breath (%)	30.1 (186/618)	17.9 (5/28)	24.9 (82/330)	32.8 (43/131)	46.8 (29/62)	40.3 (27/67)	0.001^d
Chest pain (%)	15.4 (95/618)	17.9 (5/28)	13.6 (45/330)	13.0 (17/131)	22.6 (14/62)	20.9 (14/67)	0.238^d
Fear/anxiety (%)	3.2 (20/618)	0 (0/28)	4.2 (14/330)	3.1 (4/131)	1.6 (1/62)	1.5 (1/67)	0.527^d
Other (%)	3.6 (22/618)	3.6 (1/28)	1.8 (6/330)	5.3 (7/131)	8.1 (5/62)	4.5 (3/67)	0.093^d

Mean ± standard deviation.

P-values for among-group comparisons are from the Kruskal-Wallis test.

Median (interquartile range).

P-values for among-group comparisons are from Pearson’s χ² test.

This Feature Is Available To Subscribers Only